• Gene fusion; HGNC; 76; ABL1 + HGNC; 8064; NUP214; Name(s)=NUP214-ABL1; Note=NUP214 exon 32 fused to ABL1 exon 2 (PubMed=15361874; PubMed=35354797).
  

PubMed=1706955; DOI=10.1182/blood.V77.7.1534.1534
O'Connor R., Cesano A., Lange B., Finan J., Nowell P.C., Clark S.C., Raimondi S.C., Rovera G., Santoli D.
Growth factor requirements of childhood acute T-lymphoblastic leukemia: correlation between presence of chromosomal abnormalities and ability to grow permanently in vitro.
Blood 77:1534-1545(1991)

PubMed=2039829; DOI=10.1182/blood.V77.11.2463.2463
Cesano A., O'Connor R., Lange B., Finan J., Rovera G., Santoli D.
Homing and progression patterns of childhood acute lymphoblastic leukemias in severe combined immunodeficiency mice.
Blood 77:2463-2474(1991)

Patent=US5272082
Santoli D., Rovera G., Cesano A.
Cytotoxic T-ALL cell lines and uses therefor.
Patent number US5272082, 21-Dec-1993

PubMed=11059767
Kruse C.A., Visonneau S., Kleinschmidt-DeMasters B.K., Gup C.J., Gomez G.G., Paul D.B., Santoli D.
The human leukemic T-cell line, TALL-104, is cytotoxic to human malignant brain tumors and traffics through brain tissue: implications for local adoptive immunotherapy.
Cancer Res. 60:5731-5739(2000)

DOI=10.1016/B978-0-12-221970-2.50457-5
Drexler H.G.
The leukemia-lymphoma cell line factsbook.
(In) ISBN 9780122219702; pp.1-733; Academic Press; London (2001)

PubMed=15361874; DOI=10.1038/ng1425
Graux C., Cools J., Melotte C., Quentmeier H., Ferrando A.A., Levine R., Vermeesch J.R., Stul M., Dutta B., Boeckx N., Bosly A., Heimann P., Uyttebroeck A., Mentens N., Somers R., MacLeod R.A.F., Drexler H.G., Look A.T., Gilliland D.G., Michaux L., Vandenberghe P., Wlodarska I., Marynen P., Hagemeijer A.
Fusion of NUP214 to ABL1 on amplified episomes in T-cell acute lymphoblastic leukemia.
Nat. Genet. 36:1084-1089(2004)

PubMed=17170727; DOI=10.1038/sj.leu.2404486
Sandberg Y., Verhaaf B., van Gastel-Mol E.J., Wolvers-Tettero I.L.M., de Vos J., MacLeod R.A.F., Noordzij J.G., Dik W.A., van Dongen J.J.M., Langerak A.W.
Human T-cell lines with well-defined T-cell receptor gene rearrangements as controls for the BIOMED-2 multiplex polymerase chain reaction tubes.
Leukemia 21:230-237(2007)

PubMed=35354797; DOI=10.1038/s41467-022-29224-5
Leo I.R., Aswad L., Stahl M., Kunold E., Post F., Erkers T., Struyf N., Mermelekas G., Joshi R.N., Gracia-Villacampa E., Ostling P., Kallioniemi O.-P., Pokrovskaja Tamm K., Siavelis I., Lehtio J., Vesterlund M., Jafari R.
Integrative multi-omics and drug response profiling of childhood acute lymphoblastic leukemia cell lines.
Nat. Commun. 13:1691.1-1691.19(2022)